Clinical trials: Cell Free DNA
Hereditary Diseases
Development of New Prenatal Diagnostic Tests From Maternal Blood
After extraction of the cell-free DNA circulating in maternal plasma, we aim at developing new techniques for fetal DNA enrichment to perform fetal gender determination, and indirect diagnosis of inherited diseases like Cystic…
- Trial name
- NCT00314691
- Testing
- Blood samples
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplant Recipients
Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation
This is a prospective, multicenter, observational study of kidney transplant subjects where blood specimens, intended for dd-cfDNA and other future research purposes, will be drawn after transplant
- Trial name
- DART (NCT02424227)
- Where
- 14 sites in United States
- Volunteers
- 401 people
- Sponsor
- CareDx
Non Hodgkin Lymphoma
Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS
This is a prospective descriptive monocentric study whose purpose is to describe the clonal evolution of the mutational pattern in cfDNA of a cohort of patients with Diffuse Large B-Cell Non-Hodgkin Lymphomas (DLBCL) before…
- Trial name
- LymphoSeq (NCT02339805)
- Testing
- next generation sequencing, Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Henri Becquerel
Kidney Transplant Rejection, Cell-free DNA
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
The goal of this observational study is to learn if the donor-derived cell-free DNA (dd-cfDNA) test can assess rejection in kidney transplant recipients. Participants will have blood and urine collected at their study visit.
- Trial name
- NCT07060716
- Testing
- donor-derived cell-free DNA test
- Where
- 10 sites in United States, Germany
- Volunteers
- 125 people
- Sponsor
- Insight Molecular Diagnostics
Cancer
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers.
- Trial name
- NHS-Galleri (NCT05611632)
- Testing
- Multi-cancer early detection test (Galleri test)
- Where
- United Kingdom
- Volunteers
- 142,318 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Chronic Kidney Disease
Nicotinamide Riboside Supplementation in Chronic Kidney Disease
This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease. NR is a form of vitamin B3 that may help support cellular energy metabolism.
- Trial name
- NR-CKD (NCT07693543)
- Testing
- Nicotinamide Riboside (NR)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Ovarian Neoplasms, Ovarian Cancer
Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection
The goal of this observational study is to learn whether a blood-based cell-free DNA (cfDNA) methylation assay can help detect ovarian cancer, especially early-stage ovarian cancer, in women undergoing clinical evaluation for…
- Conditions
- Ovarian Neoplasms, Ovarian Cancer, Early Detection of Cancer
- Trial name
- NCT07593833
- Testing
- Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tongji Hospital
Cell-free Methylation Markers
The Utility of Cell-free DNA Methylation Markers for Hepatocellular Carcinoma
The subjects of this study were patients with liver cancer diagnosed by physicians according to AASLD clinical criteria or pathological biopsy.
- Trial name
- NCT05573217
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- National Taiwan University Hospital
Gastric Cancer
Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer
To evaluate the clinical significance of cell free DNA (cfDNA) and circulating tumor cells (CTCs) in real-time monitoring the therapeutic response during HER2-targeted therapy in histologically confirmed HER2 positive…
- Trial name
- NCT02610218
- Testing
- CTC and cfDNA analysis
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Peking University
Cancer, Early Detection of Cancer
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
- Conditions
- Cancer, Early Detection of Cancer, Circulating Cell-free DNA
- Trial name
- PREVENT (NCT05227534)
- Testing
- OverC multi-cancer detection blood test
- Where
- China
- Volunteers
- 12,500 people, healthy volunteers welcome
- Sponsor
- Guangzhou Burning Rock Dx Co., Ltd.
Transplant;Failure,Kidney, Kidney Transplant
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
This study will compare the performance of Gene Expression Profile (GEP)/ Donor derived cell free deoxyribonucleic acid (dd-cfDNA) tests, to the following tests: Molecular Microscope (MMDx) and histopathology (study of changes in…
- Conditions
- Transplant;Failure,Kidney, Kidney Transplant, Kidney Rejection Transplant
- Trial name
- NCT05811468
- Where
- United States
- Sponsor
- Rush University Medical Center
Infertility
Study of Free DNA Content of Embryo Culture Medium as a Non-Invasive Tool for Embryo Assessment
Study of Cell Free DNA Content of Human Embryo Culture Medium as a Non-Invasive Tool for Embryo Assessment in intra cytoplasmic sperm injection Treatment Cycles.
- Trial name
- NCT02480491
- Testing
- measuring cell freeDNA
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sadat City University
Carcinoma, Hepatocellular, Hepatocellular Cancer
Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma
Effective strategies for personalized treatment decisions for early-stage hepatocellular carcinoma (HCC) remain critically limited. Microvascular invasion (MVI) is a distinctive pathological hallmark of HCC invasiveness.
- Conditions
- Carcinoma, Hepatocellular, Hepatocellular Cancer, Liver Cancer
- Trial name
- NCT05540925
- Testing
- Curative-intent liver resection
- Where
- China
- Volunteers
- 3,650 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Culture Media, DNA
Cell-free DNA: a Non-invasive Test for Assessing Embryo Quality
In the present project we propose to deeply characterize nuclear and/or mitochondrial DNA in embryo culture medium, in order to investigate whether both cell-free nucleic acid types may provide additional, reliable, predictive…
- Trial name
- NCT01397136
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Sarcoidosis With Myocarditis, Sarcoidosis
Cell Free DNA in Cardiac Sarcoidosis
Sarcoidosis is a multisystem granulomatous disease of unknown cause that can affect any organ in the body, including the heart. Granulomatous myocarditis can lead to ventricular dysfunction and ventricular arrhythmias causing…
- Conditions
- Sarcoidosis With Myocarditis, Sarcoidosis, Healthy, ST Elevation Myocardial Infarction
- Trial name
- cfDNA in CS (NCT03858777)
- Testing
- cell free DNA
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nabeel Hamzeh
Endometrial Cancer, Atypical Endometrial Hyperplasia
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
Endometrial cancer is one of the most common gynecological malignancies, and its incidence is rising. Currently, there is a lack of highly effective and non-invasive screening methods.
- Trial name
- NCT07892755
- Where
- China
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Guizhou Provincial People's Hospital
Cardiac Transplant Failure, Cardiac Transplant Rejection
Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Trial name
- D-OAR (NCT02178943)
- Where
- 28 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CareDx
Heart Transplantation
Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients
Following heart transplantation (HTx), lifelong immunosuppressive treatment is required to prevent the immune system from attacking, damaging, and rejecting the donor hear (allograft).
- Trial name
- TRANSCEND (NCT07886489)
- Testing
- Donor-derived cell free DNA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Kidney Transplant Rejection, Kidney Transplant Infection
Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients
The goal of this observational study is to learn about dynamic changes of Torquetenovirus (TTV) load in Chinese renal transplant recipients.
- Conditions
- Kidney Transplant Rejection, Kidney Transplant Infection, Virus, Immunosuppression
- Trial name
- TTV (NCT05727709)
- Where
- 5 sites in China
- Volunteers
- 220 people
- Sponsor
- Tongji Hospital
Breast Cancer, Breast Cancer (Triple Negative Type)
Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment
Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded…
- Trial name
- SENOCOHORT (NCT07833891)
- Testing
- Patients follow-up
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris